Therapeutic Antibodies And Clinical Cytokines

Question 1

Aldesleukin (IL-2)

Answer 1

Renal cell carcinoma

Metastatic melanoma

Question 2

Epoetin Alfa (erythropoietin)

Answer 2

Anemias (especially in renal failure)

Question 3

Filgrastim (G-CSF)

Answer 3

Recovery of bone marrow and WBC by granulocyte stimulation

Question 4

Sargramostim (GM-CSF)

Answer 4

Recovery of bone marrow and WBC by granulocyte and monocytes stimulation

Question 5

IFN-alpha

Answer 5

Chronic HBV/HCV
Kaposi sarcoma
Malignant melanoma
Hairy cell leukemia
Condylomata acuminata
Renal cell carcinoma

Question 6

IFN-beta

Answer 6

MS

Question 7

IFN-gamma

Answer 7

Chronic granulomatous disease

Question 8

Romiplostim (thrombopoietin analog)

Answer 8

Thrombocytopenia

Question 9

Eltrombopag (thrombopoietin receptor agonist)

Answer 9

Thrombocytopenia

Question 10

Oprelvekin (IL11)

Answer 10

Thrombocytopenia

Question 11

Alemtuzamab

Answer 11

Target CD52

CLL, MS

Question 12

Bevacizumab

Answer 12

target VEGF
CRC, RCC, non-small cell lung cancer
Neovascular age-related macular degeneration, proliferative diabetic retinopathy, and macular edema

Question 13

Cetuximab

Answer 13

Target EGFR

Stage 4 CRC, head and neck cancer

Question 14

Rituximab

Answer 14

Target CD20

B-cell non-Hodgkin lymphoma, CLL, RA, ITP

Question 15

Trastuzumab

Answer 15

Target HER2/neu

Breast cancer, gastric cancer

Question 16

Adalimumab

Answer 16

Target soluble TNF-alpha

IBD, RA, ankylosis spondylitis, psoriasis

Question 17

Certolizumab

Answer 17

Target soluble TNF-alpha

IBD, RA, ankylosis spondylitis, psoriasis

Question 18

Golimumab

Answer 18

Target soluble TNF-alpha

IBD, RA, ankylosis spondylitis, psoriasis

Question 19

Infliximab

Answer 19

Target soluble TNF-alpha

IBD, RA, ankylosis spondylitis, psoriasis

Question 20

Daclizumab

Answer 20

Target CD25 (part of IL-2 receptor)
Relapsing MS

Question 21

Eculizumab

Answer 21

Targets complement protein C5

Paroxysmal nocturnal hemoglobinuria

Question 22

Natalizumab

Answer 22

Targets alpha4-integrin (WBC adhesion)
MS, Crohn disease
Risk of PML in patients with JC virus

Question 23

Ustekinumab

Answer 23

Targets IL-12/IL-23

Psoriasis, psoriatic arthritis

Question 24

Abciximab

Answer 24

Target platelet glycoproteins 2b/3a

Antiplatelet

Question 25

Denosumab

Answer 25

Target RANKL | Osteoporosis (inhibits osteoclasts maturation--mimics osteoprotegerin)

Question 26

Digoxin immune Fab

Answer 26

Targets digoxin | Antidote

Question 27

Omalizumab

Answer 27

Targets IgE | Refractory allergic asthma, prevents IgE binding to Fc-epsilonRI

Question 28

Pavlivizumab

Answer 28

Targets RSV F protein | RSV prophylaxis for high-risk infants

Question 29

Ranibizumab

Answer 29

targets VEGF | Neovascular age-related macular degeneration, proliferative diabetic retinopathy, and macular edema